Fracture risk reduction and safety by osteoporosis treatment compared with placebo or active comparator in postmenopausal women: systematic review, network meta-analysis, and meta-regression analysis of randomised clinical trials

医学 德诺苏马布 内科学 不利影响 优势比 安慰剂 骨质疏松症 特立帕肽 唑来膦酸 科克伦图书馆 随机对照试验 肿瘤科 骨矿物 病理 替代医学
作者
Mina Nicole Händel,Isabel Cardoso,Cecilie von Bülow,Jeanett Friis Rohde,Anja Ussing,Sabrina Mai Nielsen,Robin Christensen,Jean‐Jacques Body,Maria Luisa Brandi,Adolfo Díez‐Pérez,Peyman Hadji,M K Javaid,Willem Frederik Lems,Xavier Nogués,Christian Roux,Salvatore Minisola,Andreas Kurth,Thierry Thomas,Daniel Prieto‐Alhambra,Serge Ferrari
出处
期刊: [BMJ]
卷期号:381: e068033-e068033 被引量:169
标识
DOI:10.1136/bmj-2021-068033
摘要

Abstract Objective To review the comparative effectiveness of osteoporosis treatments, including the bone anabolic agents, abaloparatide and romosozumab, on reducing the risk of fractures in postmenopausal women, and to characterise the effect of antiosteoporosis drug treatments on the risk of fractures according to baseline risk factors. Design Systematic review, network meta-analysis, and meta-regression analysis of randomised clinical trials. Data sources Medline, Embase, and Cochrane Library to identify randomised controlled trials published between 1 January 1996 and 24 November 2021 that examined the effect of bisphosphonates, denosumab, selective oestrogen receptor modulators, parathyroid hormone receptor agonists, and romosozumab compared with placebo or active comparator. Eligibility criteria for selecting studies Randomised controlled trials that included non-Asian postmenopausal women with no restriction on age, when interventions looked at bone quality in a broad perspective. The primary outcome was clinical fractures. Secondary outcomes were vertebral, non-vertebral, hip, and major osteoporotic fractures, all cause mortality, adverse events, and serious cardiovascular adverse events. Results The results were based on 69 trials (>80 000 patients). For clinical fractures, synthesis of the results showed a protective effect of bisphosphonates, parathyroid hormone receptor agonists, and romosozumab compared with placebo. Compared with parathyroid hormone receptor agonists, bisphosphonates were less effective in reducing clinical fractures (odds ratio 1.49, 95% confidence interval 1.12 to 2.00). Compared with parathyroid hormone receptor agonists and romosozumab, denosumab was less effective in reducing clinical fractures (odds ratio 1.85, 1.18 to 2.92 for denosumab v parathyroid hormone receptor agonists and 1.56, 1.02 to 2.39 for denosumab v romosozumab). An effect of all treatments on vertebral fractures compared with placebo was found. In the active treatment comparisons, denosumab, parathyroid hormone receptor agonists, and romosozumab were more effective than oral bisphosphonates in preventing vertebral fractures. The effect of all treatments was unaffected by baseline risk indicators, except for antiresorptive treatments that showed a greater reduction of clinical fractures compared with placebo with increasing mean age (number of studies=17; β=0.98, 95% confidence interval 0.96 to 0.99). No harm outcomes were seen. The certainty in the effect estimates was moderate to low for all individual outcomes, mainly because of limitations in reporting, nominally indicating a serious risk of bias and imprecision. Conclusions The evidence indicated a benefit of a range of treatments for osteoporosis in postmenopausal women for clinical and vertebral fractures. Bone anabolic treatments were more effective than bisphosphonates in the prevention of clinical and vertebral fractures, irrespective of baseline risk indicators. Hence this analysis provided no clinical evidence for restricting the use of anabolic treatment to patients with a very high risk of fractures. Systematic review registration PROSPERO CRD42019128391.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
1秒前
1秒前
1秒前
yhp完成签到 ,获得积分10
2秒前
dianpao发布了新的文献求助10
2秒前
四季刻歌完成签到,获得积分10
2秒前
zY完成签到 ,获得积分10
2秒前
wanci的应助被园园采纳,获得10
2秒前
蒲勇兵完成签到 ,获得积分10
3秒前
科研小能手的应助被香蕉山芙采纳,获得50
3秒前
俏皮钢笔完成签到 ,获得积分10
3秒前
phonetwo发布了新的文献求助10
4秒前
Mia123的应助被香蕉山芙采纳,获得10
4秒前
KKC的应助被顺心的雅绿采纳,获得10
4秒前
北北北完成签到,获得积分10
4秒前
Humingyu发布了新的文献求助10
4秒前
4秒前
wwww发布了新的文献求助10
4秒前
海岸发布了新的文献求助10
4秒前
今后的应助被露露采纳,获得10
6秒前
小蘑菇的应助被Tuniverse_采纳,获得10
6秒前
可爱的函函的应助被笨鸟先飞采纳,获得10
6秒前
scalar完成签到,获得积分10
6秒前
张伟发布了新的文献求助10
6秒前
fszking发布了新的文献求助10
7秒前
7秒前
7秒前
7秒前
珏璟发布了新的文献求助10
7秒前
怕黑成风完成签到,获得积分10
7秒前
明理越彬完成签到 ,获得积分10
8秒前
luyue9406的应助被贾贾采纳,获得10
8秒前
健忘远山完成签到,获得积分10
8秒前
Piky发布了新的文献求助10
9秒前
leclerc发布了新的文献求助10
9秒前
迷你的灵阳的应助被Doctor采纳,获得10
10秒前
李之恒完成签到,获得积分10
10秒前
景言完成签到,获得积分10
10秒前
李子梁完成签到,获得积分10
11秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8182664
求助须知:如何正确求助?哪些是违规求助? 9572061
关于积分的说明 21822050
捐赠科研通 7779160
什么是DOI,文献DOI怎么找? 3433702
关于科研通互助平台的介绍 2557882
邀请新用户注册赠送积分活动 2479766